Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study
Year: 2019
Type: article
Study design: Clinical Trial
Abstract: PURPOSE The PRIMA study (ClinicalTrials.gov identifier: NCT00140582 ) established that 2 years of rituximab maintenance after first-line immunochemotherapy significantly improved progression-free survival (PFS) in patients with follicular lymphoma compared with observation. Here, we report the final PFS and overall survival (OS) results from the PRIMA study after 9 years of follow-up and provide a final overview of safety. METHODS Patients (> 18 years of age) with previously untreated high–tumor-burden follicular lymphoma were nonrandomly assigned to receive one of three immunochemotherapy induction regimens. Responding patients were randomly assigned (stratified by induction regimen, response to induction treatment, treatment center, and geographic region) 1:1 to receive 2 years of rituximab maintenance (375 mg/m2, once every 8 weeks), starting 8 weeks after the last induction treatment, or observation (no additional treatment). All patients in the extended follow-up provided their written informed consent (data cutoff: December 31, 2016). RESULTS In total, 1,018 patients completed induction treatment and were randomly assigned to rituximab maintenance (n = 505) or observation (n = 513). Consent for the extended follow-up was provided by 607 patients (59.6%) of 1,018 (rituximab maintenance, n = 309; observation, n = 298). After data cutoff, median PFS was 10.5 years in the rituximab maintenance arm compared with 4.1 years in the observation arm (hazard ratio, 0.61; 95% CI, 0.52 to 0.73; P < .001). No OS difference was seen in patients randomly assigned to rituximab maintenance or observation (hazard ratio, 1.04; 95% CI, 0.77 to 1.40; P = .7948); 10-year OS estimates were approximately 80% in both study arms. No new safety signals were observed. CONCLUSION Rituximab maintenance after induction immunochemotherapy provides a significant long-term PFS, but not OS, benefit over observation.
Source: Journal of Clinical Oncology
DOI: 10.1200/jco.19.01073
Authors: Emmanuel Bachy, John F. Seymour, Pierre Feugier, Fritz Offner, Armando López-Guillermo, David Belada, Luc Xerri, John V. Catalano, Pauline Brice, François Lemonnier, Alejandro Martin, Olivier Casasnovas, Lars M. Pedersen, Véronique Dorvaux, David Simpson, Sirpa Leppa, Jean Gabarre, Maria G. da Silva, Sylvie Glaisner, Loic Ysebaert, Anne Vekhoff, Tanin Intragumtornchai, Steven Le Gouill, Andrew Lister, Jane A. Estell, Gustavo Milone, Anne Sonet, Jonathan Farhi, Harald Zeuner, Hervé Tilly, Gilles Salles
Institutions: Lyon 1 Université, Inserm, Hospices Civils de Lyon, The Royal Melbourne Hospital, The University of Melbourne, Centre Hospitalier Régional et Universitaire de Nancy, Nutrition-Génétique et Exposition aux Risques Environnementaux, Université de Lorraine, Ghent University, Hospital Clínic de Barcelona, Charles University, Aix-Marseille Université, Institut Paoli-Calmettes, Frankston Hospital, Monash University, Assistance Publique – Hôpitaux de Paris, Hôpital Saint-Louis, Université Paris-Est Créteil, Hôpitaux Universitaires Henri-Mondor, Instituto de Investigación Biomédica de Salamanca, Centro de Investigación Biomédica en Red de Cáncer, Herlev Hospital, Centre Hospitalier Régional de Metz-Thionville, Norwegian Meteorological Institute, North Shore Hospital, University of Helsinki, Helsinki University Hospital, Pitié-Salpêtrière Hospital, Instituto Português de Oncologia Francisco Gentil, Hôpital René Huguenin, Institut Curie, Institut universitaire du cancer de Toulouse Oncopole, Hôpital Saint-Antoine, Chulalongkorn University, Centre Hospitalier Universitaire de Nantes, Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers, Université de Nantes, Nantes Université, Queen Mary University of London, The University of Sydney, Concord Repatriation General Hospital, Centre Hospitalier Universitaire d'Angers, F. Hoffmann-La Roche AG, Centre Henri Becquerel
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W2963759094
